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1. Induction            
 
Neonatal hypoxic-ischemic encephalopathy (HIE) is an important cause of death and 
neurodevelopmental delay worldwide. Treatment for infants with hypoxic-ischemic 
encephalopathy was limited to supportive care for a long time, but efforts have been made to 
develop effective therapies. However, through several experimental therapies for hypoxic 
ischemic encephalopathy seemed promising none proved consistently successful in clinical 
studies. Despite the improvement in neonatal care in the last decades, the incident of 
neurological disabilities related to perinatal brain injury remained unchanged affecting 2-3 in 
1000 newborns. However accurate Hungarian national statistical data are not available, the 
estimated number of infants born with HIE is 150-200 in a year.  
Over the past two decades, experimental and clinical evidence has accumulated that a 
3-4
o
C reduction of body temperature maintained for at least 72 hours in newborns with 
hypoxic-ischemic encephalopathy may reduce cerebral injury and improve neurological 
outcomes. Recent clinical trials have demonstrated that prolonged cooling of either the head 
or the whole body of neonates with HIE is safe and associated with reduced short-term 
mortality and morbidity at 18 months of age.   
4 
 
 
2. Aims            
 
Our aim was to perform several observational studies on our study group while 
participating in the international, randomized TOBY trial. We felt that this trial was one of the 
last opportunities to do observations comparing a randomized hypothermic and normothermic 
study group.  
There are several questions not fully investigated in hypothermia. Our plan was to 
collect more information during prolonged systemic hypothermia about markers of 
multiorgan failure and brain injury, cytokine responses, and changes in morphine metabolism 
before hypothermia introduced as standard care. For this purpose additionally to the TOBY 
protocol we collected serial blood samples at fixed time points in term infants treated with 
hypoxic-ischemic encephalopathy. 
Our aim was to find answers for four hypotheses: 
1. We hypothesized that as the main pathogenic processes of brain injury and the 
dysfunction of other organs are partly similar after asphyxia, hypothermia believed to 
attenuate hypoxic cerebral injury could also protect organs other than brain exposed to 
hypoxia. There are just few data concerning this issue. Therefore we investigated the effect of 
hypothermia on some laboratory parameters reflecting cellular necrosis and organ dysfunction 
characteristic for the failure of internal organs in asphyxiated neonates. 
2. Secondly we wanted to evaluate the effect of systemic moderate hypothermia on 
levels of serum S100B and NSE proteins, their time course, and association with the aEEG 
and neurodevelopmental outcome as no data was available before.  
3. One of the mechanisms via hypothermia believed to act is the reduction of the 
inflammation. The aim of our next substudy was to explore the influence of therapeutic 
hypothermia on serum cytokine and cortisol concentrations.  
4. During our pilot study before the TOBY trial we observed severe late hypotension 
in some infants treated with hypothermia without clear cardiovascular cause. Discussing this 
we found that we use morphine treatment more often and in higher dose than other study 
groups, and the late cardiovascular instability can be related to morphine toxicity. Our 
hypothesis was that  morphine pharmacokinetics are altered during prolonged moderate 
systemic hypothermia in asphyxiated neonates, resulting in excessively high morphine 
concentrations compared with infants kept at normothermia. 
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3. Methods            
 
Between January 2005 and December 2007, 64 term infants were admitted to the 
regional level 3 neonatal care unit at the First Department of Pediatrics, Semmelweis 
University with the diagnosis of hypoxic-ischemic encephalopathy. These infants were 
screened for evidence of encephalopathy according to a 3-step eligibility system based on 
clinical and neurologic criteria as used in the TOBY Study. Infants were enrolled within 6 
hours of birth if each of the following criteria was fulfilled. (1) infants were ≥36 weeks’ 
gestation with ≥1 of the following: (a) Apgar score of ≤5 at 10 minutes after birth; (b) 
continued need for resuscitation, including endotracheal or mask ventilation, at 10 minutes 
after birth; (c) acidosis defined as pH ≤7.0 and/or base deficit ≥16 mmol/L in umbilical cord 
blood sample or any blood sample within 60 minutes of birth (arterial or venous blood); (2) 
moderate to- severe encephalopathy consisted of altered state of consciousness (irritability, 
lethargy, stupor, or coma) and ≥1 of the following: (a) hypotonia, (b) abnormal reflexes 
including oculomotor or pupillary abnormalities, (c) an absent or weak suck, or (d) clinical 
seizures; and (3) ≥30 minutes duration of amplitude-integrated electroencephalogram 
recording showed moderately abnormal or suppressed background amplitude-integrated 
electroencephalogram activity or seizures. Exclusion criteria from the TOBY were 
prematurity, congenital malformations, suspected metabolic disorders, absence of parental 
consent and age of more than six postnatal hours. 
From the 64 admitted infants 24 with HIE were enrolled into the multinational, 
randomized and   prospective TOBY Study (Total Body Hypothermia for the Treatment of 
Perinatal Asphyxial Encephalopathy, ISRCTN 89547571). The study was approved by the 
national Ethical Committee for Medical Research (591/KO/2004). 40 infants were not 
enrolled to the study because of the following reasons: no evidence or mild encephalopathy 
22/40, unstable infants with severe HIE 9/40, admission after 5 hours of life 2/40, congenital 
abnormality 1/40 (diaphragmal hernia), parental consent not given 5/40, lack of human 
resources 1/40. 
Before treatment, each patient’s parents provided informed consent to participate in this 
study.  
Infants allocated to treatment with standard intensive care and hypothermia were cooled to an 
aim rectal temperature of 33.5°C for 72 hours, called the hypothermia group ((HT) n =13 ).  
Infants allocated to the control group (normothermia (NT); n = 11 ) were treated with 
standard intensive care on normothermia (37°C). 
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Both groups were treated with the same regimen, except for the hypothermia. All of 
the infants were treated with a continuous infusion of morphine-hydrochloride, with the rate 
adjusted according to clinical status. 
After randomization, aEEG monitoring was continued and the background activity was 
assessed at the time points of blood sampling. Seizures were controlled with phenobarbital in 
both groups. If the infant remained agitated or seizures persisted, a single dose of midazolam 
was administered. The daily cumulative doses of morphine and other drugs were recorded. 
Cardiovascular instability was maintained as unit protocol. Blood and outer ear swab cultures 
were obtained at admission from all infants and bacterial infection was excluded. All infants 
received a regular antibiotic regimen i.e. ampicillin and amikacin during the study period. 
Venous blood samples were taken at 6, 24, 48 and 72 h after birth for laboratory 
measurements of full blood count, electrolytes, liver function (ASAT, ALAT), lactate 
dehydrogenase, creatine kinase, creatinine, uric acid, coagulation and for further 
investigations (S100, NSE, cytokine and morphine measurements). Samples were collected 
via venous umbilical catheter. Blood was centrifuged; sera were separated and stored at -80°C 
until further measurements. Laboratory measurements of 21 infants were analysed by the 
commercially available tests on a Roche Hitachi 912 system Hitachi 714 automated system. 
S100B and NSE were measured by enzyme-linked immunosorbent assay (Roche) from frozen 
sample (100 µl sera) according to the manufactures instructions. 12 cytokines and vasoactive 
agents (interleukin (IL)-1-α, IL-1-β, IL-2, IL-4, IL-6, IL-8, IL-10, MCP-1, EGF, VEGF, 
IFN-γ, TNF-α), were measured from frozen sample (100 µl sera) with the  Randox Cytokine 
and Growth factors array (Randox Lifesciences, Crumlin, United Kingdom). Serum morphine 
concentrations were determined with an enzymelinked immunosorbent assay (Opiates 
Reagent Pack, Abbott Diagnostics, Abbott Park, IL) from the frozen samples. 
Cranial ultrasound scan was performed daily during the investigation period and 
reported by radiologist consultants. Brain MRI was performed between day 5 and 14 on a 
Philips 3T scanner obtaining T1 weighted, T2 weighted, and diffusion weighted images. 
Neurodevelopmental assessment (Bayley Scales of Infant and Toddler Development TM III) 
was performed between 18-22 months according to TOBY study protocol. Infants were 
classified into two groups depending on the results of the follow up examination: Survival 
without severe disability; and severe developmental delay (MDI and PDI <70) or death. 
The analysis of the data usually was performed by the statistical software Statistica 8.0 
(StatSoft Inc, Tulsa, USA). Anthropometric and clinical parameters were compared with 
Mann-Whitney and Fischer tests. The level of significance was set at p<0.05. 
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4. Results            
 
The clinical characteristics of the infants in the HT and NT groups were similar. The 
time of admission was (median [range]) 1.8 [0.8-4.4] hours of age in the HT and 1.3 [1.0-4.5] 
hours in NT groups. The time of randomization was 3.3 (2.5-5.3) hours of age in the HT and 
3.1 (2.2-5.5) hours in NT groups. Clinical parameters used to assess the severity of HIE 
(Apgar scores, pH base excess and lactate within the first hour of life, Sarnat scores) showed 
no significant difference between the two groups. 
Area under curve values of aspartate aminotransferase (ASAT), lactate dehydrogenase 
(LDH), uric acid and creatinine during the investigated period and alanine aminotransferase 
(ALAT) value at 72 h were lower in neonates on hypothermia than in those on normothermia 
(Figure 1.). Renal failure and liver impairment affected less hypothermic than normothermic 
neonates (3/12 vs. 7/9, p = 0.03, 3/12 vs. 6/9 p = 0.08, respectively). Four of the 12 
hypothermic and 6 of the 9 normothermic neonates developed multiorgan failure. 
 
Serum S100B and NSE levels were grossly elevated in both hypothermic and 
normothermic groups. Compared to values at 6 hours of age, S100B values decreased over 
time in both groups (NT: p=0.002, HT: p=0.04). Serum S100B values were lower in 
hypothermic infants compared to normothermic infants (p=0.047 at 48 hours). Serum S100B 
(Figure 2.) and NSE values were significantly higher in infants who died or developed severe 
neurological impairment (S100B, p<0.05 at all time points; NSE, p=0.036 at 24 hours of age).  
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Figure 1. Changes of serum ASAT (a), LDH (b), creatinine (c) and uric acid (d) during the 
first 72 h of life in asphyxiated neonates treated with hypothermia or on normothermia. 
Values are given as median [range]. * significant difference between hypothermic and 
normothermic group, p < 0.05. 
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Figure 2. Serum S100B levels in the groups with or without adverse 
outcome. Median (indicated by the horizontal line) and individual values 
were shown. 
 
IL-6 levels (at 6 hours of age) (Figure 3.) and IL-4 levels (during first 24 hours) were 
significantly lower in asphyxiated neonates treated with hypothermia compared to 
normothermic neonates.  
The duration of hypothermia correlated with lower levels of IL-6 (p=0.02), INF-γ(p=0.05), 
and TNF-α (p=0.04) levels measured at 6 hours of age and IL-10 levels at 12 hours (p=0.01). 
Cortisol levels did not differ significantly between neonates on hypothermia and 
normothermia at any time points. At 24 hours of age, 7/8 (87.5%) neonates in the 
normothermic, and 9/10 (90%) of the hypothermia group presented with cortisol levels lower 
than 414 nmol/L suggestive for relative adrenal insufficiency. At 72 hours of age neither 
significant differences between groups, nor significant correlation between cortisol and 
cytokine levels were observed. 
 
Figure 3. Changes in serum IL-6 in hypothermic and normothermic infants. Median and 
interquartile range was shown. *, significantly different from normothermia (p<0.05), #, 
significantly different from values measured at 6
 
hours of age (p<0.05). 
9 
 
 
Serum morphine concentrations at 24 to 72 hours after birth were (median [range]) 
292 ng/mL (137–767 ng/mL) in the HT infants and 206 ng/mL (88–327 ng/mL) in the infants 
on normothermia, despite similar morphine infusion rates and cumulative doses. Morphine 
concentrations correlated with morphine infusion rate, cumulative dose, and treatment with 
hypothermia. Serum morphine concentrations reached a steady state after 24 hours in the NT 
infants but continued to increase throughout the assessment period in the HT group. Morphine 
clearance was low in both groups: (median [range]) morphine clearance estimated from area 
under the curve was 0.69 mL/min per kg (0.58–1.21 mL/min per kg) in hypothermic group 
and 0.89 mL/min per kg (0.65–1.33 mL/min per kg) in infants on normothermia. Serum 
morphine concentrations >300 nL/mL occurred more often in the hypothermia group and 
when the morphine infusion rate was >10 μg/kg per h.  
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Figure 1. Relation between serum morphine 
concentrations and infusion rates in asphyxiated 
neonates treated with hypothermia or on normothermia.  
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5. Conclusion            
 
Our aim was to perform several observational studies on our study group while 
participating in the international, randomized TOBY trial. Our contribution helped to reach 
the desired patient number in the TOBY trial to answer the question about the efficacy of 
moderate systemic hypothermia treatment in HIE, and for us provided a reliable background 
for our publications. Since then, as hypothermia is clarified as standard care in HIE, it would 
be difficult to repeat our studies because of ethical reasons. 
Our studies reported original data about comparing hypothermic and normothermic 
groups of term asphyxiated neonates in some aspects like markers of multiorgan failure and 
neuronal injury, inflammatory markers, and morphine metabolism.  
1. We concluded first that systemic moderate hypothermia decreases the acute cell 
necrosis caused by hypoxic ischemic insult and may attenuate organ dysfunction in neonatal 
asphyxia.  
 2. We found that infants treated with moderate hypothermia had lower serum S100B 
levels compared with normothermic infants and serum NSE did not show clinically 
significant differences compared with the cooled infants. Serum S100B and NSE levels were 
significantly higher in the infants who died or had a severely abnormal neurological outcome 
but the association was stronger for serum S100B levels. These data suggest that serum 
S100B levels may be a useful biomarker of disease and treatment effect in studies of 
neuroprotective therapies following perinatal asphyxia. 
3. Our other observation was that serum IL-6 levels were significantly lower in the 
hypothermia group at 6 hours of age suggesting that hypothermia may decrease immediately 
the early rise of IL-6 following asphyxia. Moreover a significant negative correlation between 
IL-6 levels at 6 hours of age and the duration of hypothermia,  suggesting a “dose dependent”  
reducing effect of hypothermia on early rise of IL -6 serum levels.   
4. Finally we published first  that asphyxiated neonates treated with moderate systemic 
hypothermia receiving commonly used rates of morphine infusion for 72 hours developed 
higher and potentially toxic concentrations of morphine compared with normothermic infants, 
despite receiving similar cumulative morphine doses. These observations resulted changes in 
the analgesic treatment of infants treated with hypothermia, being more cautious about 
morphine dosage. Also has led to more extensive investigations about pharmacokinetics of 
frequently used drugs during hypothermia in neonates.  
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The main limitation of our studies is the very small patient number. However we 
included all neonates enrolled to the TOBY study during this period with available blood 
samples.  Further studies would be required to confirm some of our findings, like the early 
changes seen in IL-6 levels, but this now may be difficult for ethical reason since moderate 
hypothermia is an accepted neuroprotective intervention for neonatal hypoxic-ischemic 
encephalopathy. 
Continuation of data collection is vital for finding answers for the outstanding 
questions about hypothermia treatment in the future, and national cooling registers should be 
set up for these purposes – also in Hungary. Long term neurodevelopmental follow-up for 
these children also remains essential. 
At the moment, several potential neuroprotective agents are waiting for human clinical 
trials in the next few years. As outcome measurements have improved, in the near future 
smaller clinical studies need to be carried out to assess the effectiveness of additional 
therapies combined with hypothermia. Brain MRI can be used as marker for brain injury, 
which can reduce the length of clinical studies assessing new therapies. New techniques like 
spectroscopy, diffusion weighted and diffusion tension imaging can assess the injury 
accurately and provide information about prognosis. However new MRI techniques for these 
newborns are often not available because of scanner availability and difficulties with 
transport. Serum biomarkers like S100B protein as we showed can also have future role in 
monitoring therapy effectiveness. 
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